About H2-Pharma
H2-Pharma is a Healthcare company based in Montgomery (United States) founded in 2013, and was acquired by ANI Pharmaceuticals in February 2016. Distributor of generic pharmaceutical drugs. Its chief executive, as recorded, is Brooke Cantey. H2-Pharma offers products and services including Branded Pharmaceuticals, Generic Pharmaceuticals, and Non-Rx Products. Its focus areas include Pharmaceutical Distributors and Generic Drugs. Its legal entity is H2-Pharma, LLC. Its competitors include AmerisourceBergen, Pfizer and Renee; 2 of its 3 listed competitors have raised funding.
Company details
H2-Pharma was founded in 2013 and is headquartered in Montgomery, United States. Operations center on the distribution of generic pharmaceutical drugs within the healthcare sector. Supplies are provided to pharmacies, hospitals, and other providers across various markets. The company is led by Brooke Cantey, serving as CEO and President. Its online presence is maintained through the domain h2-pharma.com, supporting logistical and informational needs.
- Headquarters Montgomery, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website h2-pharma.com
- Social LinkedIn
- Acquired by ANI Pharmaceuticals (Feb 2016)
- Legal Name H2-Pharma, Llc
- InvestorsANI Pharmaceuticals
& 1 more
- Acquired byANI Pharmaceuticals
(Feb 2016)
Products & Services of H2-Pharma
H2-Pharma offers a comprehensive portfolio of products and services, including Branded Pharmaceuticals, Generic Pharmaceuticals, and Non-Rx Products.
Sales and distribution of branded medications for various health needs.
Affordable alternatives for branded drugs in the pharmaceutical market.
Distribution of non-prescription health products to customers.
Funding Insights of H2-Pharma
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of H2-Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | Seed | – | Ardian | – |
2 investors in total: 2 institutional.
Investors in H2-Pharma
H2-Pharma has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include ANI Pharmaceuticals and Ardian.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private investment firm specializing in markets and partnerships. | ardian.com | |||
Branded and generic prescription drugs are developed, manufactured, and marketed. | 1996 | anipharmaceuticals.com | Baudette, United States |
Investor details for H2-Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of H2-Pharma
1 people are tracked at H2-Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Brooke Cantey | CEO & President | Leadership |
Complete people profiles for H2-Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of H2-Pharma
3 dated milestones of H2-Pharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded H2-Pharma is founded.
- Exit Acquired by ANI Pharmaceuticals.
- Funding First funding round.
Competitors of H2-Pharma
H2-Pharma has 3 listed competitors in our database, 2 of them funded. They include AmerisourceBergen, Pfizer and Renee.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amerisourcebergen.com | 1985 | Chesterbrook, United States | 46,000 | Pharmaceutical distribution and supply chain services are provided globally. | ||
| pfizer.com | 1849 | New York, United States | $8M | Pharmaceutical products for treating multiple diseases are provided. | ||
| renee.com | 2021 | Los Angeles, United States | $8.2M | Diversified drugs are distributed by Renee in the United States. |
Detailed competitors of H2-Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of H2-Pharma
The website of H2-Pharma (h2-pharma.com) receives about 4.6K visits a month.
- Monthly visits4.6K
▼ 6% vs previous month
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as H2-Pharma (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about H2-Pharma
Complete news archive for H2-Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about H2-Pharma
H2-Pharma was founded in 2013 and raised its 1st funding round 7 years after it was founded.
H2-Pharma is headquartered in Montgomery, United States. It is registered at Montgomery, Alabama, United States.
Brooke Cantey is the CEO of H2-Pharma, as recorded in our data.
H2-Pharma was founded in 2013 and is headquartered in Montgomery, United States. Operations center on the distribution of generic pharmaceutical drugs within the healthcare sector. Supplies are provided to pharmacies, hospitals, and other providers across various markets. The company is led by Brooke Cantey, serving as CEO and President. Its online presence is maintained through the domain h2-pharma.com, supporting logistical and informational needs.
H2-Pharma's top competitors include Pfizer, AmerisourceBergen and Renee.
H2-Pharma offers Branded Pharmaceuticals, Generic Pharmaceuticals, and Non-Rx Products.
H2-Pharma has 2 investors. Key investors include ANI Pharmaceuticals, and Ardian.
H2-Pharma operates through H2-Pharma, Llc.
Yes. H2-Pharma was acquired by ANI Pharmaceuticals in February 2016.